The degree of expression of vascular endothelial growth factor receptor 2 (VEGFR2) in tumor vessels has been shown to be variable and dependent on the type of tumor and this fact might have an effect on tumor responses to VEGF pathway inhibiting antiangiogenic drugs [44]. Here, KDR is linked to neoplasm.